HROW Stock Overview
An eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for HROW from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Harrow, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.22 |
| 52 Week High | US$59.23 |
| 52 Week Low | US$9.13 |
| Beta | 0.67 |
| 1 Month Change | -19.37% |
| 3 Month Change | -23.99% |
| 1 Year Change | 223.75% |
| 3 Year Change | 271.96% |
| 5 Year Change | 334.26% |
| Change since IPO | 295.67% |
Recent News & Updates
Harrow: The Triesence Relaunch
Dec 14Harrow: Spotlight On IHEEZO
Nov 16Harrow's Focus - Reviving Old Drugs In A Crowded Market
Oct 02Recent updates
Harrow: The Triesence Relaunch
Dec 14Harrow: Spotlight On IHEEZO
Nov 16Harrow's Focus - Reviving Old Drugs In A Crowded Market
Oct 02Harrow: 3 Business Models, One Mission
Sep 10Borrowing Cash To Burn It: The Curious Case Of Harrow
Aug 21Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
May 02Harrow's Drug Iheezo Is Off To A Great Start
Feb 19Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Jan 30Harrow sells non‑ophthalmic compounding business, terms undisclosed
Oct 05Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye
Sep 27SRK Capital - Harrow Health: Market Missing The Forest For The Trees
Aug 19These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively
Aug 11
Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch
May 23Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
May 12Is Harrow Health (NASDAQ:HROW) A Risky Investment?
Dec 15Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
Aug 24Shareholder Returns
| HROW | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.6% | -2.0% | -3.5% |
| 1Y | 223.7% | 7.6% | 22.1% |
Return vs Industry: HROW exceeded the US Pharmaceuticals industry which returned 7.6% over the past year.
Return vs Market: HROW exceeded the US Market which returned 22.1% over the past year.
Price Volatility
| HROW volatility | |
|---|---|
| HROW Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HROW has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HROW's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 315 | Mark Baum | www.harrow.com |
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.
Harrow, Inc. Fundamentals Summary
| HROW fundamental statistics | |
|---|---|
| Market cap | US$1.23b |
| Earnings (TTM) | -US$33.41m |
| Revenue (TTM) | US$169.14m |
7.2x
P/S Ratio-36.5x
P/E RatioIs HROW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HROW income statement (TTM) | |
|---|---|
| Revenue | US$169.14m |
| Cost of Revenue | US$46.41m |
| Gross Profit | US$122.73m |
| Other Expenses | US$156.13m |
| Earnings | -US$33.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 72.56% |
| Net Profit Margin | -19.75% |
| Debt/Equity Ratio | 322.9% |
How did HROW perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 00:32 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Harrow, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |